Clinical Rheumatology

, Volume 38, Issue 12, pp 3459–3469 | Cite as

Clinical spectrums and outcomes of necrotizing autoimmune myopathy versus other idiopathic inflammatory myopathies: a multicenter case-control study

  • Khemmapop Yongchairat
  • Jantima Tanboon
  • Jariya Waisayarat
  • Pongthorn Narongroeknawin
  • Parawee Chevaisrakul
  • Charungthai Dejthevaporn
  • Wanruchada KatchamartEmail author
Original Article



To investigate the clinical characteristics, laboratory features, and treatment outcomes of Thai patients compared between those with necrotizing autoimmune myopathy (NAM) and those with other idiopathic inflammatory myopathies (IIMs) or non-NAM.


This multicenter case-control study included patients aged ≥ 18 years who were diagnosed with IIMs by muscle pathology, and who had relevant clinical and laboratory data, including muscle enzymes, from at least 3 follow-up visits during a 1-year period. Baseline clinical and laboratory data were recorded. Serum myositis-specific autoantibodies (MSAs) were obtained on the date of recruitment.


Of the 70 included patients, 67% had NAM, and 33% had non-NAM. The mean age of patients was 50.5 ± 15.9 years, 67% were female, and the median duration of symptoms was 2 months (IQR, 1–4). History of cancer was significantly higher in non-NAM (21.7% vs. 2.1%, p = 0.01). Gottron’s papules were significantly more prevalent in non-NAM (21.7% vs. 4.3%, p = 0.04). Non-NAM had a higher prevalence of anti-Mi-2a (17.4% vs. 2.1%, p = 0.04) and Mi-2b (17.4% vs. 0.0%, p = 0.01); however, the presence of other MSAs, including anti-HMGCR and anti-SRP, was similar between groups. Improvement in motor power and treatment intensification with glucocorticoid and/or immunosuppressive agents 3 times throughout the follow-up period was similar between groups (NAM 46.8% vs. non-NAM 34.8%, p = 0.34).


NAM is indistinguishable from non-NAM by clinical manifestations, serology, or laboratory findings, except that pathognomonic skin sign of Gottron’s papules and anti-Mi2 are suggestive of dermatomyositis. The integration of clinical, serological, and pathological data is essential for making a diagnosis of NAM.

Key Points

NAM is indistinguishable from non-NAM by clinical manifestations, serology, or laboratory findings.

• The integration of clinical, serological, and pathological data is essential for making a diagnosis of NAM.


Anti-HMGCR Idiopathic inflammatory myopathy Myositis-specific autoantibodies Necrotizing autoimmune myopathy Outcomes 



The authors gratefully acknowledge Mrs. Phakhamon Thaweeratthakul, BSc (nursing), MSc (public health), for blood sample collection; Ms. Khemajira Karaketklang, BSc (nursing), MPH, for statistical analysis; Assoc. Prof. Ronnachai Viriyataweekul, MD, of the Department of Clinical Pathology for technical support; and Mr. Chakriwong Ma-on and Ms. Ampa Changnam of the Department of Pathology for slide preparation.

Authors’ contributions

All authors made substantial contributions to the conception, design of the work, the acquisition, analysis, interpretation of data, drafted the work or substantively revised it, and approved the submitted version.

Funding disclosure

This study was funded by a Siriraj Research Grant from the Faculty of Medicine Siriraj Hospital, Mahidol University (grant no. R 016132020).

Compliance with ethical standards

The protocol for this study was approved by the Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University (COA no. SI 040/2018), the Ethical Clearance Committee on Human Rights Related to Research Involving Human Subjects of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (MURA) (COA no. 2018/57), and the Institutional Review Board Committee of the Royal Thai Army Medical Department (IRBRTA) (COA no. S068h/60). All procedures performed in this study that involved human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standard. Written informed consent was obtained from all individual participants included in this study.




  1. 1.
    Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407. CrossRefPubMedGoogle Scholar
  2. 2.
    Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347. CrossRefPubMedGoogle Scholar
  3. 3.
    Liang C, Needham M (2011) Necrotizing autoimmune myopathy. Curr Opin Rheumatol 23(6):612–619. CrossRefPubMedGoogle Scholar
  4. 4.
    Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14(5):337–345. CrossRefPubMedGoogle Scholar
  5. 5.
    van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, de Visser M (2003) Polymyositis: an overdiagnosed entity. Neurology 61(3):316–321CrossRefGoogle Scholar
  6. 6.
    Klein M, Mann H, Plestilova L, Zamecnik J, Betteridge Z, McHugh N, Vencovsky J (2015) Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology (Oxford) 54(11):2010–2014. CrossRefGoogle Scholar
  7. 7.
    Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M (2015) Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA neurology 72(9):996–1003. CrossRefPubMedGoogle Scholar
  8. 8.
    Rodriguez Cruz PM, Luo YB, Miller J, Junckerstorff RC, Mastaglia FL, Fabian V (2014) An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord 24(12):1025–1035. CrossRefPubMedGoogle Scholar
  9. 9.
    Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL (2015) The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 52(2):189–195. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, Suzuki S, Suzuki N, Nishino I (2017) Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology 88(5):493–500. CrossRefPubMedGoogle Scholar
  11. 11.
    Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, Garcia-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, International Myositis A, Clinical Studies G, the Paediatric Rheumatology International Trials O (2017) 2016 American College of Rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 69(5):898–910. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Watanabe Y, Suzuki S, Nishimura H, Murata KY, Kurashige T, Ikawa M, Asahi M, Konishi H, Mitsuma S, Kawabata S, Suzuki N, Nishino I (2015) Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore) 94(4):e416. CrossRefGoogle Scholar
  13. 13.
    Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C, Phillips J, Mammen A, Van Damme P, Westhovens R, Ghirardello A, Doria A, Choi MY, Fritzler MJ, Schmeling H, Muro Y, Garcia-De La Torre I, Ortiz-Villalvazo MA, Bizzaro N, Infantino M, Imbastaro T, Peng Q, Wang G, Vencovsky J, Klein M, Krystufkova O, Franceschini F, Fredi M, Hue S, Belmondo T, Danko K, Mahler M (2016) Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev 15(10):983–993. CrossRefPubMedGoogle Scholar
  14. 14.
    Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, Maisonobe T, Dubourg O, Behin A, Laforet P, Stojkovic T, Eymard B, Costedoat-Chalumeau N, Campana-Salort E, Tournadre A, Musset L, Bader-Meunier B, Kone-Paut I, Sibilia J, Servais L, Fain O, Larroche C, Diot E, Terrier B, De Paz R, Dossier A, Menard D, Morati C, Roux M, Ferrer X, Martinet J, Besnard S, Bellance R, Cacoub P, Arnaud L, Grosbois B, Herson S, Boyer O, Benveniste O (2014) Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 93(3):150–157. CrossRefGoogle Scholar
  15. 15.
    Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, Lester S (2015) Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52(2):196–203. CrossRefPubMedGoogle Scholar
  16. 16.
    Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL (2017) More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford) 56(5):787–794. CrossRefGoogle Scholar
  17. 17.
    Ayesha SM, Meena AK, Vangala N, Rajasekhar L, Kaul S, Borgahain R, Uppin MS (2018) Necrotizing autoimmune myopathy: clinicopathologic study from a single tertiary care centre. Ann Indian Acad Neurol 21(1):62–67. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, Suzuki N, Nishino I (2016) Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87(10):1038–1044. CrossRefPubMedGoogle Scholar
  19. 19.
    Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325(21):1487–1498. CrossRefPubMedGoogle Scholar
  20. 20.
    Scola R, Werneck L, Prevedello D, Toderke E, Iwamoto F (2000) Diagnosis of dermatomyositis and polymyositis: a study of 102 cases. Arq Neuropsiquiatr 58(3B):789–799CrossRefGoogle Scholar
  21. 21.
    Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL (2015) The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42(8):1448–1454CrossRefGoogle Scholar
  22. 22.
    Mammen AL, Casciola-Rosen L, Christopher-Stine L, Lloyd TE, Wagner KR (2015) Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology-Neuroimmunology Neuroinflammation 2(6):e172CrossRefGoogle Scholar
  23. 23.
    Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62(9):2757–2766. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ellis E, Ann Tan J, Lester S, Tucker G, Blumbergs P, Roberts-Thomson P, Limaye V (2012) Necrotizing myopathy: clinicoserologic associations. Muscle Nerve 45(2):189–194. CrossRefPubMedGoogle Scholar
  25. 25.
    Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, Lloyd TE, Mammen AL (2012) Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 64(12):4087–4093. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63(3):713–721. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Shinjo SK, Nascimento JJ, Marie SK (2015) The effect of prior corticosteroid use in muscle biopsies from patients with dermatomyositis. Clin Exp Rheumatol 33(3):336–340PubMedGoogle Scholar
  28. 28.
    Pinhata MM, Nascimento JJ, Marie SK, Shinjo SK (2015) Does previous corticosteroid treatment affect the inflammatory infiltrate found in polymyositis muscle biopsies? Clin Exp Rheumatol 33(3):310–314PubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Khemmapop Yongchairat
    • 1
  • Jantima Tanboon
    • 2
  • Jariya Waisayarat
    • 3
  • Pongthorn Narongroeknawin
    • 4
  • Parawee Chevaisrakul
    • 5
  • Charungthai Dejthevaporn
    • 6
  • Wanruchada Katchamart
    • 1
    Email author
  1. 1.Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand
  2. 2.Department of Pathology, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand
  3. 3.Department of Pathology, Faculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand
  4. 4.Rheumatic Disease Unit, Department of Internal MedicinePhramongkutklao Hospital and Phramongkutklao College of MedicineBangkokThailand
  5. 5.Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand
  6. 6.Division of Neurology, Department of Medicine, Faculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand

Personalised recommendations